A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Merck Sharp & Dohme LLC
QuantumLeap Healthcare Collaborative
NeoImmuneTech
Tizona Therapeutics, Inc
Essen Biotech
Novartis
Hummingbird Bioscience
NuCana plc
Medicenna Therapeutics, Inc.
Duke University
Intensity Therapeutics, Inc.
Carisma Therapeutics Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
Simcha IL-18, Inc.
Astellas Pharma Inc
Salubris Biotherapeutics Inc
Kineta Inc.
M.D. Anderson Cancer Center
Oncorus, Inc.
Tesaro, Inc.
Syndax Pharmaceuticals
Lytix Biopharma AS